Maropitant

Last updated
Maropitant
Maropitant.svg
Clinical data
Pronunciation /məˈrɒpɪtænt/ mə-ROP-i-tant
Trade names Cerenia, Prevomax, Vetemex
Other names(2S,3S)-2-Benzhydryl-N-(5-tert-butyl-2-methoxybenzyl) quinuclidin-3-amine, maropitant citrate (USAN US)
AHFS/Drugs.com International Drug Names
License data
Routes of
administration 		Oral, subcutaneous, Intravenous
Drug class Antiemetic
ATCvet code
Legal status
Legal status
  • CA: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability Oral: 20–30% dogs, 50% cats
SQ: 90% (both)
Protein binding 99.5%
Metabolism Liver (CYP3A12 and CYP2D15)
Metabolites CJ-18,518
Elimination half-life 6–8 hours (SQ)
Duration of action 24 hours (SQ)
Identifiers
  • (2S,3S)-N-(5-tert-Butyl-2-methoxybenzyl)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octan-3-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C32H40N2O
Molar mass 468.685 g·mol−1
3D model (JSmol)
  • O=C(O)C(O)(CC(=O)O)CC(=O)O.O.O(c1ccc(cc1CN[C@@H]2[C@@H](N3CCC2CC3)C(c4ccccc4)c5ccccc5)C(C)(C)C)C
  • InChI=1S/C32H40N2O.C6H8O7.H2O/c1-32(2,3)27-15-16-28(35-4)26(21-27)22-33-30-25-17-19-34(20-18-25)31(30)29(23-11-7-5-8-12-23)24-13-9-6-10-14-24;7-3(8)1-6(13,5(11)12)2-4(9)10;/h5-16,21,25,29-31,33H,17-20,22H2,1-4H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);1H2/t30-,31-;;/m0../s1 Yes check.svgY
  • Key:PGVSXRHFXJOMGW-YBZGWEFGSA-N Yes check.svgY
   (verify)

Maropitant (INN; [1] brand name: Cerenia, used as maropitant citrate (USAN), is a neurokinin-1 (NK1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs [2] [3] and in 2012, for cats. [4]

Contents

Maropitant has mild pain-relieving, anti-anxiety and anti-inflammatory effects.[ medical citation needed ]

Veterinary uses

Injectable maropitant is used in dogs to treat and prevent acute vomiting; tablets are used for preventing vomiting from a variety of causes, though it requires a higher dose to prevent vomiting from motion sickness. The injectable version is also licensed for preventing and treating acute vomiting in cats. [5] [3] [6] [7]

Maropitant is effective in treating vomiting from a variety of causes, including gastroenteritis, chemotherapy, and kidney failure; [8] [9] when given beforehand, it can prevent vomiting caused by using an opioid as a premedication. [6] [10] Some have claimed that maropitant is better at treating vomiting than nausea, pointing to cats with chronic kidney disease who, when receiving maropitant, had a reduction in vomiting but no corresponding increase in appetite. [4]

Maropitant has been used in acute cases of rapid or labored breathing to prevent vomiting that could lead to aspiration pneumonia. [11] It has been given in combination with a benzodiazepine to cats prior to stressful events (such as a veterinary visit) to possibly relieve hypersensitivity. [12]

When compared to other antiemetics, maropitant has similar or greater effectiveness to chlorpromazine and metoclopramide for centrally mediated vomiting induced by apomorphine or xylazine. [7] It works better than chlorpromazine and metoclopramide for vomiting peripherally induced induced with syrup of ipecac. [13] Unlike dimenhydrinate and acepromazine, which are used for motion sickness, maropitant does not cause sedation. [14]

Maropitant has been used as an adjunct treatment in severe bronchitis due to its weak anti-inflammatory effects. [11] It alleviates visceral pain and has been found to reduce the amount of general anesthesia (both sevoflurane and isoflurane) needed in some operations. [8] [15]

Some believe that maropitant can be used in rabbits and guinea pigs to relieve pain caused by ileus (impaired bowel movements), though it lacks antiemetic effects in rabbits, who cannot vomit. [16]

Maropitant is given orally, subcutaneously, and intravenously. [3]

Contraindications

Maropitant is only indicated for dogs at least 16 weeks old, as some very young puppies suffered bone marrow hypoplasia (incomplete development ). [3] It should also not be used in animals with suspected GI obstruction or toxin ingestion. [9] [14]

It is not recommended to give maropitant for more than five consecutive days, as it tends to accumulate in the body due to one of the liver enzymes responsible for its metabolism, CYP2D15, becoming saturated. However, there have been studies where beagles who were given maropitant for two weeks in a row showed no signs of toxicity. [14]

Because maropitant is metabolized by the liver, caution should be taken when giving it to dogs with liver dysfunction. [3] [8] Caution should also be taken when giving it with other drugs that are also highly protein-bound, such as NSAIDs, anticonvulsants, and some behavior-modifying drugs; [3] such drugs compete with maropitant for binding to plasma proteins, increasing the concentration of unbound maropitant in the blood. [17] Maropitant should also not be used with calcium channel antagonists (used to treat high blood pressure) or in animals with heart disease, as it has a slight affinity for calcium and potassium channels. [18]

Side effects

Maropitant is safer than other antiemetics used in veterinary medicine, in part because of its high specificity for its target and thus not binding to other receptors in the central nervous system. [4] Side effects in dogs and cats include hypersalivation, diarrhea, loss of appetite, and vomiting. [8] [12] Eight percent of dogs taking maropitant at doses meant to prevent motion sickness vomited right after, likely due to the local effects maropitant had on the gastrointestinal tract. Small amounts of food beforehand can prevent such post-administration vomiting. [7]

One of the most common side effects of subcutaneous administration is moderate to severe pain at the injection site. [6] Although the manufacturer recommends keeping maropitant at room temperature, many people have noted that keeping it in the fridge reduces the sting upon injection. Only unbound maropitant causes pain – it is normally formulated with beta-cyclodextrin to increase solubility; at cooler temperatures, more of the maropitant remains bound to the cyclodextrin, leaving less maropitant unbound. [10] [16]

While there is no pain related to the intravenous administration of maropitant, pushing a dose in too quickly can temporarily reduce blood pressure. [6] [14]

Fewer than 1 in 10,000 dogs and cats experience anaphylactic reactions. [18]

Overdose

Signs of maropitant overdose include lethargy, irregular or labored breathing, lack of muscle coordination, and tremors. Overdose of the oral formulation can cause salivation and nasal discharge, while overdose of intravenous maropitant can sometimes lead to reddish urine. [8] The LD50 is high, being over 2,000 mg/kg for oral maropitant in rats. [19]

Packaging of injectable maropitant (Cerenia), as sold by Zoetis Injectable Cerenia.jpg
Packaging of injectable maropitant (Cerenia), as sold by Zoetis

Pharmacology

Mechanism of action

Vomiting is caused when impulses from the chemoreceptor trigger zone (CRTZ) in the brain are sent to the vomiting center in the medulla. Motion sickness specifically occurs when signals to the CRTZ originate from the inner ear: motion is sensed by the fluid of the semicircular canals, which causes overstimulation. The signal travels to the brain's vestibular nuclei, then to the CRTZ, and finally to the vomiting center. [20]

Maropitant has a similar structure to substance P, the key neurotransmitter in causing vomiting, which allows it to act as an antagonist and bind to the substance P receptor neurokinin 1 (NK1). [3] [21] It is highly selective for NK1 over NK2 and NK3. [6] [16] Maropitant binds to the neurokinin receptors in the vagus nerves leaving the GI tract, as well as to receptors in the CRTZ and the vomiting center. [13] [20] By virtue of working at the last step in triggering vomiting, it can prevent a broader range of stimuli than most antiemetics can. [21] It is effective against emetogens that act at the central nervous system (such as apomorphine in dogs and xylazine in cats), those that act in the periphery (e.g. syrup of ipecac), [10] [14] and those that act in both (e.g. cisplatin). [7]

Packaging of oral maropitant Oral Cerenia.jpg
Packaging of oral maropitant

Pharmacokinetics

Maropitant's bioavailability is unaffected by the presence of food. [8] Bioavailability is 91% at the standard subcutaneous dose but 24% at the standard oral dose; the standard oral dose is higher to partially compensate for incomplete bioavailability. [3] [14] It binds to plasma proteins at a rate of 99.5%; it has a low volume of distribution (9 L/kg) and is thus not extensively absorbed. [3] [6] Subcutaneously administered maropitant had peak plasma concentration around half an hour after administration; the mean half-life is 6–8 hours, and a single dose lasts 24 hours in dogs. [6] Orally administered maropitant reached its peak plasma concentration within two hours. [8]

Maropitant undergoes 1st-pass metabolism by liver enzymes, mainly CYP2D15 (which has high affinity for maropitant and clears over 90% of it) but also by the lower-affinity CYP3A12. [7] [8] Repeat dosing of maropitant eventually saturates CYP2D15, causing the drug to accumulate due to reduced clearance. [3] Thus, it is recommended to not use maropitant for more than five days straight, and to have a two-day rest period to allow maropitant to clear the body to prevent accumulation. [14] [22] Maropitant has over 21 metabolites, though its major one (produced by hydroxylation) is CJ-18,518. [8]

Maropitant clearance is slower in cats. [14]

Related Research Articles

An antiemetic is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer. They may be used for severe cases of gastroenteritis, especially if the patient is dehydrated.

Postoperative nausea and vomiting (PONV) is the phenomenon of nausea, vomiting, or retching experienced by a patient in the postanesthesia care unit (PACU) or within 24 hours following a surgical procedure. PONV affects about 10% of the population undergoing general anaesthesia each year. PONV can be unpleasant and lead to a delay in mobilization and food, fluid, and medication intake following surgery.

<span class="mw-page-title-main">Acepromazine</span> Antipsychotic medication

Acepromazine, acetopromazine, or acetylpromazine is a phenothiazine derivative antipsychotic drug. It was used in humans during the 1950s as an antipsychotic, but is now almost exclusively used on animals as a sedative and antiemetic. Its closely related analogue, chlorpromazine, is still used as an antipsychotic in humans. Acepromazine is used primarily as a chemical restraint in hyperactive or fractious animals.

<span class="mw-page-title-main">Albendazole</span> Chemical compound

Albendazole is a broad-spectrum anthelmintic and antiprotozoal agent of the benzimidazole type. It is used for the treatment of a variety of intestinal parasite infections, including ascariasis, pinworm infection, hookworm infection, trichuriasis, strongyloidiasis, taeniasis, clonorchiasis, opisthorchiasis, cutaneous larva migrans, giardiasis, and gnathostomiasis, among other diseases.

<span class="mw-page-title-main">Aprepitant</span> Chemical compound

Aprepitant, sold under the brand name Emend among others, is a medication used to prevent chemotherapy-induced nausea and vomiting (CINV) and to prevent postoperative nausea and vomiting (PONV). It may be used together with ondansetron and dexamethasone. It is taken by mouth or administered by intravenous injection.

<span class="mw-page-title-main">Meloxicam</span> Nonsteroidal anti-inflammatory drug (NSAID)

Meloxicam, sold under the brand name Mobic among others, is a nonsteroidal anti-inflammatory medication (NSAID) used to treat pain and inflammation in rheumatic diseases and osteoarthritis. It is used by mouth or by injection into a vein. It is recommended that it be used for as short a period as possible and at a low dose.

<span class="mw-page-title-main">Dolasetron</span> Pharmaceutical drug

Dolasetron (trade name Anzemet) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much antiemetic effect when symptoms are due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.

<span class="mw-page-title-main">Tachykinin peptides</span>

Tachykinin peptides are one of the largest families of neuropeptides, found from amphibians to mammals. They were so named due to their ability to rapidly induce contraction of gut tissue. The tachykinin family is characterized by a common C-terminal sequence, Phe-X-Gly-Leu-Met-NH2, where X is either an Aromatic or an Aliphatic amino acid. The genes that produce tachykinins encode precursor proteins called preprotachykinins, which are chopped apart into smaller peptides by posttranslational proteolytic processing. The genes also code for multiple splice forms that are made up of different sets of peptides.

<span class="mw-page-title-main">Deracoxib</span> Chemical compound

Deracoxib is a nonsteroidal anti-inflammatory drug (NSAID) of the coxib class, used in dogs to treat pain associated with osteoarthritis, or to prevent pain following orthopedic or dental surgery. It is available as beef-flavored tablets.

<span class="mw-page-title-main">Vomiting</span> Involuntary, forceful expulsion of stomach contents, typically via the mouth

Vomiting is the involuntary, forceful expulsion of the contents of one's stomach through the mouth and sometimes the nose.

Neurokinin 1 (NK1) antagonists (-pitants) are a novel class of medications that possesses unique antidepressant, anxiolytic, and antiemetic properties. NK-1 antagonists boost the efficacy of 5-HT3 antagonists to prevent nausea and vomiting. The discovery of neurokinin 1 (NK1) receptor antagonists was a turning point in the prevention of nausea and vomiting associated with cancer chemotherapy.

The consumption of grapes and raisins presents a potential health threat to dogs. Their toxicity to dogs can cause the animal to develop acute kidney injury with anuria. The phenomenon was first identified by the Animal Poison Control Center (APCC), run by the American Society for the Prevention of Cruelty to Animals (ASPCA). Approximately 140 cases were seen by the APCC in the one year from April 2003 to April 2004, with 50 developing symptoms and seven dying.

<span class="mw-page-title-main">Tepoxalin</span> Chemical compound

Tepoxalin, sold under the brand name Zubrin among others, is a non-steroidal anti-flammatory drug (NSAIDs) generally used in veterinary medicine to reduce swelling in animals with osteoarthritis. In rare circumstances, tepoxalin can also be used in human pharmacology to relieve pain caused by musculoskeletal conditions such as arthritis and hip dysplasia.

5-HT<sub>3</sub> antagonist Anti-nausea group of medications

The 5-HT3 antagonists, informally known as "setrons", are a class of drugs that act as receptor antagonists at the 5-HT3 receptor, a subtype of serotonin receptor found in terminals of the vagus nerve and in certain areas of the brain. With the notable exceptions of alosetron and cilansetron, which are used in the treatment of irritable bowel syndrome, all 5-HT3 antagonists are antiemetics, used in the prevention and treatment of nausea and vomiting. They are particularly effective in controlling the nausea and vomiting produced by cancer chemotherapy and are considered the gold standard for this purpose.

<span class="mw-page-title-main">Atipamezole</span> Veterinary drug

Atipamezole, is a synthetic α2 adrenergic receptor antagonist indicated for the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. Its reversal effect works by competing with the sedative for α2-adrenergic receptors and displacing them. It is mainly used in veterinary medicine, and while it is only licensed for dogs and for intramuscular use, it has been used intravenously, as well as in cats and other animals. There is a low rate of side effects, largely due to atipamezole's high specificity for the α2-adrenergic receptor. Atipamezole has a very quick onset, usually waking an animal up within 5 to 10 minutes.

<span class="mw-page-title-main">Nausea</span> Medical symptom or condition

Nausea is a diffuse sensation of unease and discomfort, sometimes perceived as an urge to vomit. While not painful, it can be a debilitating symptom if prolonged and has been described as placing discomfort on the chest, abdomen, or back of the throat.

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes debilitating symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

<span class="mw-page-title-main">Rolapitant</span> Pharmaceutical drug

Rolapitant (INN, trade name Varubivə-ROO-bee in the US and Varuby in the European Union) is a drug originally developed by Schering-Plough and licensed for clinical development by Tesaro, which acts as a selective NK1 receptor antagonist (antagonist for the NK1 receptor). It has been approved as a medication for the treatment of chemotherapy-induced nausea and vomiting (CINV) after clinical trials showed it to have similar or improved efficacy and some improvement in safety over existing drugs for this application.

<span class="mw-page-title-main">Polysulfated glycosaminoglycan</span> Injectable drug

Polysulfated glycosaminoglycan (PSGAG), sold under the brand name Adequan, is an injectable drug for dogs and horses that is used to alleviate the limpness, pain, and lowered range of motion caused by arthritis. It is made of repeat disaccharide units (comprising hexosamine and hexuronic acid), and is similar to glycosaminoglycans already present in the cartilage; PSGAG thus easily integrates itself there. In vitro studies have shown it to inhibit the enzymes that degrade cartilage and bone, as well as suppress inflammation and stimulate the synthesis of replacement cartilage. While it can cause an increased risk of bleeding, it is relatively safe and has a high LD50. PSGAG is one of the most widely prescribed joint treatments for horses.

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 52" (PDF). World Health Organization. 2004. pp. 254–255. Retrieved 17 November 2016.
  2. ↑ "Cerenia (maropitant citrate) Injectable Solution, Dogs" (PDF). Food and Drug Administration . Retrieved 2011-04-19.
  3. 1 2 3 4 5 6 7 8 9 10 Package Insert for Cerenia at Pfizer Animal Health (full detailed drug information)
  4. 1 2 3 Riviere JE, Papich MG (2017). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. p. 2828. ISBN   978-1-118-85588-1.
  5. ↑ "FDA Approves First Drug To Prevent and Treat Vomiting in Dogs". US Food & Drug Administration. 28 February 2007. Archived from the original on 2016-10-24. Retrieved 18 May 2018.
  6. 1 2 3 4 5 6 7 CVMP assessment report for Cerenia new route of administration (intravenous use) for the solution for injection (PDF) (Report). European Medicines Agency. 10 April 2015.
  7. 1 2 3 4 5 Maddison JE, Page SW, Church DB (2008). Small Animal Clinical Pharmacology. Elsevier Health Sciences. p. 474. ISBN   978-0-7020-2858-8.
  8. 1 2 3 4 5 6 7 8 9 Plumb DC (2011). "Maropitant Citrate". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wis.; Ames, Iowa: Wiley. pp. 624–626. ISBN   978-0-470-95964-0.
  9. 1 2 Cote E (2010). Clinical Veterinary Advisor - E-Book: Dogs and Cats. Elsevier Health Sciences. pp. 33, 189, 208, 304, 444. ISBN   978-0-323-06876-5.
  10. 1 2 3 Grimm KA, Lamont LA, Tranquilli WJ, Greene SA, Robertson SA (2015). Veterinary Anesthesia and Analgesia: The Fifth Edition of Lumb and Jones. John Wiley & Sons. p. 248. ISBN   978-1-118-52620-0.
  11. 1 2 Tamborini A (November 2016). "Maropitant & Canine Chronic Bronchitis" (PDF). Clinician's Brief. Retrieved 29 March 2018.
  12. 1 2 Rodan I, Heath S (2015). Feline Behavioral Health and Welfare - E-Book. Elsevier Health Sciences. p. 260. ISBN   978-1-4557-7402-9.
  13. 1 2 Ettinger SJ, Feldman EC (2009). Textbook of Veterinary Internal Medicine - eBook. Elsevier Health Sciences. p. 200, 1513. ISBN   978-1-4377-0282-8.
  14. 1 2 3 4 5 6 7 8 Trepanier LA (February 2015). "Maropitant: Novel Antiemetic" (PDF). Clinician's Brief. Retrieved 28 March 2018.
  15. ↑ Swallow A, Rioja E, Elmer T, Dugdale A (July 2017). "The effect of maropitant on intraoperative isoflurane requirements and postoperative nausea and vomiting in dogs: a randomized clinical trial". Veterinary Anaesthesia and Analgesia. 44 (4): 785–793. doi:10.1016/j.vaa.2016.10.006. PMID   28844293.
  16. 1 2 3 Le K (1 October 2017). "Maropitant". Journal of Exotic Pet Medicine. 26 (4): 305–309. doi:10.1053/j.jepm.2017.08.007. ISSN   1557-5063.
  17. ↑ Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2016). Rang & Dale's Pharmacology (8th ed.). Edinburgh: Elsevier. p. 107. ISBN   978-0-7020-5362-7. OCLC   903234097.
  18. 1 2 "Contra-indications, warnings, etc". NOAH Compendium. National Office of Animal Health. Retrieved 11 May 2018.
  19. ↑ Bahri L (September 2009). "Maropitant: A novel treatment for acute vomiting in dogs". dvm360.com. Retrieved 28 March 2018.
  20. 1 2 Graham H (June 2013). "Motion Sickness in Small Animals: Pathophysiology & Treatment" . Clinician's Brief. Retrieved 29 March 2018.
  21. 1 2 Bahri L (1 September 2009). "Maropitant's pharmacokinetics and pharmacology". dvm360.com. Retrieved 2 May 2018.
  22. ↑ Nelson RW, Couto CG (2014). Small Animal Internal Medicine - E-Book. Elsevier Health Sciences. p. 418. ISBN   978-0-323-24300-1.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.